Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
Patent 6132771 Issued on October 17, 2000. Estimated Expiration Date: 
February 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPharmaceutical preparation for oral use Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith Multiple unit pharmaceutical preparation Multiple unit tableted dosage form of omeprazole Patent #: 5817338 InventorsAssigneeApplicationNo. 750936 filed on 02/13/1997US Classes:424/468, Sustained or differential release type424/460, Containing proteins or derivatives thereof (e.g., gelatin, etc.)424/469, Discrete particles in supporting matrix424/470, Where particles are granulated424/475, Organic coatings424/480, Cellulose or derivative424/482, Containing solid synthetic polymers424/490, Coated (e.g., microcapsules)514/925ULCER TREATMENTExaminersPrimary: Page, Thurman K.Assistant: Seidleck, Brian K. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/22A61K 009/30 A61K 009/26 A61K 009/50 Foreign Application Priority Data1996-01-08 SEAbstractAn oral pharmaceutical dosage form comprising a proton pump inhibitor and one or more prokinetic agents in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of multilayered tablets, capsules or multiple unit tableted dosage forms. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with gastro oesophageal reflux diseases.Other References
Field of SearchSustained or differential release typeWith claimed perfecting feature in contents (e.g., excipient, lubricant, etc.) Printed, embossed, grooved, or perforated Organic coatings Discrete particles in supporting matrix Cellulose derivatives Cellulose or derivative Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Coated (e.g., microcapsules) Where particles are granulated Coated pills or tablets Containing proteins or derivatives thereof (e.g., gelatin, etc.) Containing solid synthetic polymers ULCER TREATMENT | |
